1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc.

AOBI
American Oriental Bioengineering, Inc.US flagOther OTC
0.00
USD
- -
- -
88.00Market Cap
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
TTM
Revenue per Share
70.95
774.74
960.52
672.99
953.44
1,251.32
1,761.39
2,301.45
3,466.14
3,977.15
4,097.83
2,847.95
1,897.99
1,666.13
Basic EPS, GAAP
-1,679.94
130.05
106.15
148.45
231.79
306.96
466.82
620.83
616.36
556.26
188.68
-903.16
-781.08
-1,247.3
Free Cash Flow per Basic Share
-1,175.73
-1.52
140.43
81.22
189.26
126.67
395.75
589.61
-1,281.87
301.75
28.53
-86.24
-903.69
-762.97
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-5,638.53
-156.04
361.38
272.93
484.35
678.62
941.44
1,465.57
1,962.4
2,568.42
2,780.52
1,850.26
1,028.42
315.72
Tangible Book Value per Share
-1,610.06
- -
794.31
597.08
737.47
1,879.59
1,933.08
3,115.3
1,882.78
2,546.11
3,045.98
2,546.4
1,984.47
1,716.58
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
8
10
21
32
55
110
160
265
296
306
213
145
122
Operating Margin (%)
-3,668.99
18.32
22.93
27.47
31.42
33.51
33.02
32.54
23.99
19.84
9.93
-1.08
-37.89
-36.53
Depreciation Expense
- -
- -
- -
2
2
2
3
5
10
12
13
12
12
12
Net Income, GAAP
-1
1
1
5
8
13
29
43
47
41
14
-67
-60
-91
Effective Tax Rate (%)
- -
14.26
22.04
19.84
22.19
24.69
20.25
17.3
21.16
24.24
39.9
- -
- -
- -
Profit Margin (%)
-2,367.68
16.79
11.05
22.06
24.31
24.53
26.5
26.98
17.78
13.99
4.6
-31.71
-41.15
-74.86
Working Capital
- -
1
3
11
15
67
92
180
87
131
162
27
-11
-62
LT Debt
- -
- -
- -
- -
- -
- -
1
2
116
116
116
1
1
5
Total Equity
-1
- -
8
19
33
91
156
313
350
395
431
381
328
284
Return on Invested Capital (%)
- -
209.41
32.2
30.76
26.84
20.84
22.19
17.61
12.51
8.88
3.38
- -
- -
- -
Return on Capital (%)
- -
-155.59
43.78
60.46
49.68
49.05
56.54
47.47
25.19
15.34
5.41
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
74.84
62.93
58.47
65.94
53.75
37.34
24.29
7.06
-39.01
-55.09
-132.78

Capital Structure

FRC

•

in mil. unless spec.
Mar'13
Jun'13
Sep'13
ST Debt
62
64
88
LT Borrowings
1
1
5
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
4
6
4

Working Capital

FRC

•

in mil. unless spec.
Mar'13
Jun'13
Sep'13
Total Current Assets
75
68
65
Cash, Cash Equivalents & STI
6
7
3
Accounts Receivable, Net
32
29
27
Inventories
22
21
21
Total Current Liabilities
103
104
126
Payables & Accruals
41
40
39
ST Debt
62
64
88
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
55.29%
1.63%
-14.06%
Free Cash Flow
63.99%
3.77%
972.72%
Net Income, GAAP
-4.39%
-131.91%
-11.47%
Sales/Revenue/Turnover
39.38%
3.57%
-31.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
52
54
54
53
213
2012
26
27
29
62
145
2013
21
20
18
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
10.85
36.44
102.46
- -
-903.16
2012
-217.74
-328.65
256.07
- -
-781.08
2013
-288.69
-176.28
-290.36
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Shujun Liu
Full Time Employees
3,719
Sector
Healthcare
Industry
Biotechnology
Address
1 First Liangshuihe Avenue Beijing BE People's Republic of China 100176
IPO Date
Dec 12, 2001
Website
bioaobo.com
Similar Companies
immatics biotechnologies GmbH (IMTXW)
Intellipharmaceutics International Inc. (IPCIF)
Sangamo Therapeutics, Inc. (SGMOQ)
Bionomics Limited (BNOX)
AnGes, Inc. (4563.T)
Lytix Biopharma AS (LYTIX.OL)
Business
American Oriental Bioengineering, Inc. (AOBI) develops, manufactures, and markets pharmaceutical and healthcare products derived from traditional Chinese medicine. The company offers a range of proprietary product lines including Plantago Seed Extract Powder for respiratory health; Jiang Huang capsules and tablets for anti-inflammatory and cardiovascular support; and Shuang Huang Lian tablets, capsules, and oral liquids for immune system enhancement and cold symptom relief; along with Yu Xing Cao capsules for anti-bacterial applications and Kang Hua tablets for throat and respiratory conditions. Additional offerings encompass dietary supplements such as Vita Health Tablets for nutritional support and beauty products like Facial Beauty Capsules and Mask; as well as functional foods including sugar-free functional drinks and functional beverages targeting wellness markets in China. Founded in 1992 and headquartered in Wanchai, Hong Kong, with primary manufacturing and operations in the People's Republic of China, the company serves pharmaceutical wholesalers, distributors, retail chains, and hospitals primarily within the domestic Chinese market, focusing on the traditional Chinese medicine and over-the-counter healthcare segments. No significant recent partnerships, acquisitions, funding rounds, product launches, or strategic shifts have been reported for the company in the last 1-2 years, reflecting a period of operational stability amid its established product portfolio.